Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

[1]  P. Quirke,et al.  Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Cristofanilli,et al.  Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer , 2016, Breast Cancer Research and Treatment.

[3]  Peter C. Austin,et al.  Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis , 2016, Statistics in medicine.

[4]  J. Barrett,et al.  HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials , 2016, The Journal of pathology.

[5]  A. Hinke,et al.  Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[6]  M. D. James,et al.  Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial , 2015, Journal of Clinical Pathology.

[7]  J. Barrett,et al.  HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC) , 2015 .

[8]  M. Wiese,et al.  Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer , 2015, British Journal of Cancer.

[9]  R. Butler,et al.  Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial , 2014, The Lancet. Oncology.

[10]  M. Parmar,et al.  Evaluating many treatments and biomarkers in oncology: a new design. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Patrick Royston,et al.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.

[12]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[13]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[14]  Paul D. Smith,et al.  AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer , 2010, Clinical Cancer Research.

[15]  Patrick Royston,et al.  A Menu-Driven Facility for Sample-Size Calculation in Novel Multiarm, Multistage Randomized Controlled Trials with a Time-to-Event Outcome , 2009 .

[16]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[17]  P. Harari,et al.  Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members , 2008, Oncogene.

[18]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[19]  Linda Mol,et al.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.

[20]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[21]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[22]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[23]  R. Berardi,et al.  The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. , 2011, The oncologist.

[24]  T. Hickish,et al.  Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. , 2011, The Lancet. Oncology.

[25]  K. Pavelić,et al.  Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival , 2000, Journal of Cancer Research and Clinical Oncology.